Added to YB: 2025-04-11
Pitch date: 2025-02-21
CPH.TO [bullish]
Cipher Pharmaceuticals Inc.
+52.55%
current return
Author Info
No bio for this author
Company Info
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Market Cap
CAD 330.8M
Pitch Price
CAD 12.54
Price Target
N/A
Dividend
N/A
EV/EBITDA
13.65
P/E
12.45
EV/Sales
6.52
Sector
Pharmaceuticals
Category
growth
Cipher Pharmaceuticals Inc. - $CPH.TO
CPH.TO: Cipher Pharma doubled EBITDA w/ Parapro acquisition. Natroba (scabies/lice) key growth driver in US, Canada, ROW. Potential in-housing of Absorica. Mgmt exploring 2-3 $30M+ revenue opportunities. High margins (50%+ EBITDA), asset-light model. 10-36% EBITDA CAGR potential. Trades at 10x EV/EBITDA. Terclara & Piclidenison upside.
Read full article (9 min)